Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
IMMUN.ST - Mendus AB (publ)
Q1 2026 Mendus AB (publ) Earnings Call
May 08, 2026 / 08:00AM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Independent of MRD status. So it will be a little bit more granular as compared to the ADVANCE 2 trial where we immediately already started to see some patients converting from an MRD positive to an MRD negative status. This will be a little bit more granular with respect on how MRD evolves over time.
But nevertheless, it will give us a good indication about what is happening under the surface. And similarly, and also very similar to what we did in the ADVANCE 2 trial, we will of course look for the response of the immune system, both at baseline.
And also in correlation with the outcome with respect to the health of the patients, so whether the patients relapse or not, but also over time follow the immune responses that
Trustpilot
